Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Generation Bio Co. stock logo
GBIO
Generation Bio
$0.35
+3.0%
$0.38
$0.30
$3.65
$22.99M2.59395,068 shs676,584 shs
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$32.09
-0.1%
$33.20
$26.47
$41.61
$1.85B0.83631,656 shs287,680 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$298.49
-0.6%
$291.28
$200.63
$377.46
$6.64B-1.05359,776 shs108,674 shs
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$3.65
$3.65
$2.71
$6.65
$381.02M0.93.64 million shsN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$11.49
-0.6%
$10.43
$5.35
$16.15
$626.77M1.14672,891 shs185,804 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Generation Bio Co. stock logo
GBIO
Generation Bio
0.00%+15.85%-4.81%-6.58%-85.74%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.00%+0.34%-8.39%+9.67%+3.88%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%-0.75%+8.90%-5.06%+9.87%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00%0.00%0.00%0.00%+36.19%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
0.00%-1.25%+5.56%+93.35%-9.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Generation Bio Co. stock logo
GBIO
Generation Bio
2.9667 of 5 stars
3.53.00.00.00.03.31.3
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
4.7951 of 5 stars
4.61.00.00.02.83.34.4
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
4.0894 of 5 stars
3.40.00.04.62.23.30.6
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.7618 of 5 stars
3.10.00.04.70.01.70.6
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3.9352 of 5 stars
3.60.00.04.81.80.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Generation Bio Co. stock logo
GBIO
Generation Bio
3.00
Buy$7.332,007.28% Upside
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
3.13
Buy$53.6367.11% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.89
Moderate Buy$420.6340.92% Upside
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.13
Hold$8.45131.51% Upside
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3.29
Buy$23.20102.00% Upside

Current Analyst Ratings Breakdown

Latest RVNC, MDGL, HRMY, GBIO, and STOK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
6/2/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$61.00
5/15/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.00
5/14/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/14/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$47.00 ➝ $35.00
5/13/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
Generation Bio Co. stock logo
GBIO
Generation Bio
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
5/6/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$49.00 ➝ $49.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$441.00 ➝ $458.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$422.00 ➝ $460.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$394.00 ➝ $420.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Generation Bio Co. stock logo
GBIO
Generation Bio
$19.89M1.17N/AN/A$1.29 per share0.27
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$714.73M2.58$2.94 per share10.91$11.56 per share2.78
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$317.38M20.88N/AN/A$34.59 per share8.63
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$234.04M1.63N/AN/A($1.73) per share-2.11
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$190.91M3.28N/AN/A$4.32 per share2.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Generation Bio Co. stock logo
GBIO
Generation Bio
-$131.67M-$1.08N/AN/AN/A-292.92%-75.84%-30.40%8/6/2025 (Estimated)
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$145.49M$2.6212.2510.320.4820.53%24.32%15.92%8/5/2025 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$465.89M-$18.05N/AN/AN/A-123.38%-50.54%-37.19%8/6/2025 (Estimated)
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$88.98M$0.7914.54N/AN/A26.33%19.08%15.72%8/5/2025 (Estimated)

Latest RVNC, MDGL, HRMY, GBIO, and STOK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Generation Bio Co. stock logo
GBIO
Generation Bio
-$0.25-$0.22+$0.03-$0.22$1.70 million$8.72 million
5/6/2025Q1 2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.59$0.78+$0.19$0.78$184.26 million$184.73 million
5/1/2025Q1 2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Generation Bio Co. stock logo
GBIO
Generation Bio
N/AN/AN/AN/AN/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/AN/AN/AN/AN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Generation Bio Co. stock logo
GBIO
Generation Bio
N/A
8.43
8.43
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.22
3.67
3.63
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.17
5.91
5.58
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/A
4.12
3.05
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A
8.41
8.41
CompanyEmployeesShares OutstandingFree FloatOptionable
Generation Bio Co. stock logo
GBIO
Generation Bio
15067.04 million52.42 millionOptionable
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
20057.42 million43.87 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9022.20 million17.43 millionOptionable
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
500104.39 million99.07 millionOptionable
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
10054.60 million49.41 millionOptionable

Recent News About These Companies

DONE DEAL: Stoke snap up Man City striker Mubama
Mubama set for Stoke loan switch
STOK Stoke Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Generation Bio stock logo

Generation Bio NASDAQ:GBIO

$0.35 +0.01 (+2.99%)
Closing price 07/3/2025 03:42 PM Eastern
Extended Trading
$0.35 0.00 (0.00%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Harmony Biosciences stock logo

Harmony Biosciences NASDAQ:HRMY

$32.09 -0.02 (-0.06%)
Closing price 07/3/2025 03:51 PM Eastern
Extended Trading
$32.18 +0.09 (+0.28%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$298.48 -1.67 (-0.55%)
Closing price 07/3/2025 03:39 PM Eastern
Extended Trading
$298.48 0.00 (0.00%)
As of 07/3/2025 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Revance Therapeutics stock logo

Revance Therapeutics NASDAQ:RVNC

$3.65 0.00 (0.00%)
As of 02/6/2025

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Stoke Therapeutics stock logo

Stoke Therapeutics NASDAQ:STOK

$11.48 -0.07 (-0.56%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$11.48 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.